Chemotherapy-induced cardiomyopathy (Q37867085)

24 August 2017

1 reference

title

Chemotherapy-induced cardiomyopathy (English)

1 reference

24 August 2017

1 reference

Syed Wamique Yusuf

1

1 reference

24 August 2017

Nasreen A Ilias-Khan

series ordinal

2

1 reference

24 August 2017

Jean-Bernard Durand

series ordinal

3

1 reference

24 August 2017

publication date

1 February 2011

1 reference

Expert Review of Cardiovascular Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

9

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

231-243

1 reference

MDGs: chronic diseases are not on the agenda

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Serum cardiac troponin I levels and ECG/Echo monitoring in breast cancer patients undergoing high-dose (7 g/m(2)) cyclophosphamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Detection of myocardial dysfunction during cancer chemotherapy with tissue Doppler imaging: a canary in the coal mine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Elevated B-type natriuretic peptide levels after anthracycline administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Biomarkers in acute cardiac disease: the present and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Combined utility of brain natriuretic peptide and cardiac troponin T may improve rapid triage and risk stratification in normotensive patients with pulmonary embolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Significance and interpretation of elevated troponin in septic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiac troponins as biomarkers of drug- and toxin-induced cardiac toxicity and cardioprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Assessment of left ventricular ejection fraction and regional wall motion with 64-slice multidetector CT: a comparison with two-dimensional transthoracic echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

The diagnostic accuracy of 64-slice computed tomography coronary angiography compared with stress nuclear imaging in emergency department low-risk chest pain patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Monitoring chemotherapy-induced cardiotoxicity: role of cardiac nuclear imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Non-invasive in vivo imaging of myocardial apoptosis and necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiotoxicity induced by chemotherapy and antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Late doxorubicin-associated cardiotoxicity in children. The possible role of intercurrent viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Prognostic importance of comorbidity in a hospital-based cancer registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Risk factors for doxorubicin-induced congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiac toxicity 4 to 20 years after completing anthracycline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiotoxicity of doxorubicin: effects of 21-aminosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

The impairment of essential fatty acid metabolism as a key factor in doxorubicin-induced damage in cultured rat cardiomyocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Doxorubicin cardiotoxicity: diastolic cardiac myocyte dysfunction as a result of impaired calcium handling in isolated cardiac myocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Myocarditis associated with doxorubicin cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Anthracycline cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Protective effects of carvedilol against anthracycline-induced cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Acute leukaemia in bcr/abl transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Acute cardiac failure after sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Congestive heart failure is a rare event in patients receiving imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

High-dose ifosfamide is associated with severe, reversible cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Side Effects of Ifosfamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiotoxicity of cytotoxic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiovascular risk in long-term survivors of testicular cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

5-Fluorouracil-induced coronary vasospasm

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Monoclonal antibodies in the treatment of malignancy: basic concepts and recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Coronary ischemia related to alemtuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Reversible cardiomyopathy induced by interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Impact of aspirin therapy in cancer patients with thrombocytopenia and acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

NT-ProBNP in non-ST-elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Usefulness of cardiac resynchronization therapy in patients with Adriamycin-induced cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Acute cardiac functional and morphological changes after Anthracycline infusions in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Intricacies of bevacizumab-induced toxicities and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

Disease and Disadvantage in the United States and in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERC.10.188

21 January 2018

Identifiers

DOI

10.1586/ERC.10.188

1 reference

24 August 2017

1 reference